Yale SPORE in Lung Cancer News
Novel Selective Biomarker May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer
A novel selective biomarker (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer, according to findings presented at the 2023 San Antonio Breast Cancer Symposium.
- December 04, 2023
A team of researchers led by senior author Dr. David Rimm and first author Charles “Jack” Robbins at Yale Cancer Center evaluated a new “selective” biomarker called Troplex™, which assesses HER2, TROP2, and cytokeratin using quantitative immunofluorescence.
- December 01, 2023Source: SWOG
The unique public-private partnership that for almost a decade has undergirded the first National Cancer Institute (NCI)-sponsored precision medicine clinical trial in lung cancer can serve as a model for future clinical research that is more rapid, innovative, and inclusive.
- December 01, 2023
On November 30, 2023, Smilow Cancer Hospital and Yale Cancer Center hosted the ACS CAN CT Forum.
- November 28, 2023
New Advanced Diagnostic Tests Lab to Perform, Interpret Clinical-grade Molecular Testing of Biomarkers
The Yale Advanced Diagnostic Tests Laboratory in the Department of Pathology, a new unit of Yale Pathology Laboratories, offers access to novel molecular tests to external users, performing and interpreting clinical grade and high-quality molecular analysis of human tissue samples.
- November 28, 2023
Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9.
- November 16, 2023
Roy S. Herbst, MD, PhD, participates in a Q&A for Lung Cancer Awareness Month.
- November 14, 2023Source: CT Public
Connecticut ranks second nationwide for early diagnosis and five-year survival of lung cancer, but sharp disparities persist in early detection and treatment for Black, Latino, and Pacific Islander populations. That’s according to new data released Tuesday by the American Lung Association. The report found Connecticut’s overall lung cancer survival rates across all ethnic groups are higher than the national average. Connecticut also ranked second nationally in early diagnosis of lung cancer. But Dr. Roy Herbst, deputy director of Yale Cancer Center said, “the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.”
- November 07, 2023
Yale Team Shares Importance of Lung Cancer Screening at Community Event at Q House in New Haven.
- November 01, 2023
A genetic variant that is linked to faster progression of multiple sclerosis (MS) has been identified in a genome-wide association study.